Inicio>>Signaling Pathways>> Others>>Laquinimod (ABR-215062)

Laquinimod (ABR-215062) (Synonyms: ABR-215062)

Catalog No.GC10474

Laquinimod (ABR-215062) (ABR-215062), un derivado de carboxamida disponible por vÍa oral, es un inmunomodulador potente que previene la neurodegeneraciÓn y la inflamaciÓn en el sistema nervioso central.

Products are for research use only. Not for human use. We do not sell to patients.

Laquinimod (ABR-215062) Chemical Structure

Cas No.: 248281-84-7

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO) Please Inquire Please Inquire
5mg
92,00 $
Disponible
10mg
148,00 $
Disponible
50mg
362,00 $
Disponible
100mg
603,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

ABR-215062 is an orally active immunoregulator. Experimental autoimmune encephalomyelitis (EAE) is an inflammatory autoimmune disease of the CNS that can be elicited in rodents and represents the major animal model for the study of multiple sclerosis (MS).

In vitro: ABR-215062 was shown to completely inhibit the development of murine acute experimental autoimmune encephalomyelitis (EAE) [1].

In vivo: ABR-215062 dose-dependently inhibited disease and showed better disease inhibitory effects as compared to roquinimex (Linomide). Furthermore, ABR-215062 inhibited the inflammation of both CD4+ T cells and macrophages into central nervous tissues [2].

Clinical trial: Randomized, controlled clinical trials in relapsing MS demonstrate a dose–response effect of ABR-215062 on disease activities, indicated by reduced clinical relapse rate, number of brain MRI active lesions, and sustained disability and brain atrophy [3].

References:
[1] Brunmark C, Runström A, Ohlsson L, Sparre B, Brodin T, Aström M, Hedlund G.  The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2002 Sep;130(1-2):163-72.
[2] Yang JS, Xu LY, Xiao BG, Hedlund G, Link H.  Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol. 2004 Nov;156(1-2):3-9.
[3] Haggiag S, Ruggieri S, Gasperini C.  Efficacy and safety of laquinimod in multiple sclerosis: current status. Ther Adv Neurol Disord. 2013 Nov;6(6):343-52.

Reseñas

Review for Laquinimod (ABR-215062)

Average Rating: 5 ★★★★★ (Based on Reviews and 26 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Laquinimod (ABR-215062)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.